Item 2. Management’s Discussion and Analysis
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and related notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and notes for the year ended December 31, 2020, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 25, 2021.
This discussion and other parts of this report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled “Risk Factors.” Except as may be required by law, we assume no obligation to update these forward-looking statements or the reasons that results could differ from these forward-looking statements.
Overview
We are a clinical stage biopharmaceutical company. Our strategy is to focus our efforts on the development of immune modulator product candidates to treat viral associated cancers, T-cell lymphomas, other cancers and autoimmune diseases. We have built a pipeline of five programs, three of which are in clinical development.
Our lead product candidate is mupadolimab (formerly CPI-006), a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. In both preclinical and in vivo studies in cancer patients and patients with COVID-19, mupadolimab has demonstrated binding to various immune cells and the inducement of a humoral adaptive immune response. We believe mupadolimab has the potential to be an important new therapeutic agent with a novel mechanism of action for the treatment of a broad range of cancers and infectious diseases. In February 2021, we initiated a Phase 3 trial evaluating mupadolimab in a global, randomized, double-blind trial designed to evaluate the efficacy and safety of mupadolimab compared to placebo in hospitalized patients with mild-to-moderate COVID-19. On July 15, 2021, we announced that we discontinued our Phase 3 clinical trial due to positive trends exhibited by COVID-19 vaccines in lowering serious infection and hospitalization. The discontinuation is not related to any safety or efficacy issues observed in study patients. Up to the date of discontinuation, the trial had enrolled 40 patients, who were randomized into one of three arms and received either 1.0 mg/kg or 2.0 mg/kg of mupadolimab, or placebo. The primary endpoint of the study was to be the proportion of patients that progress to requiring mechanical ventilation or death within 28 days of dosing. Although the number of patients enrolled in the trial is too small to draw definitive conclusions, we will be analyzing various clinical and laboratory data from the patients enrolled in the trial and plan to report this information later in 2021.
Mupadolimab is a unique antibody that is designed to bind to a critical epitope involved in B cell signaling. Our work in both cancer and viral diseases such as COVID-19 have provided important insights and data into how we may best utilize the biologic properties of our antibody candidate in the clinic. Across the treatment of cancer and COVID-19, one of the common factors in patients where mupadolimab has shown activity is the presence of viral antigens such as the SARS-CoV-2 virus, or in the case of patients with human papilloma virus (“HPV+”) head and neck cancer, the presence of HPV antigens. Our studies have uncovered a novel mechanism of action: mupadolimab is designed to activate B cells which may then be driven into antibody producing plasma cells by the presence of viral antigens within the tumor. Recent work by two other academic groups have shown that B cells present within the tumors of head and neck cancers produce HPV specific antibodies. As published in Nature in 2020, other groups have also shown that B cell infiltration in other tumors are strong predictors of response to immunotherapies---more predictive than T cells.
HPV+ head and neck cancers are increasing in incidence in the United States and are now more common than head and neck cancers associated with tobacco use. From 1990 to 2005 there was a 225% increase in HPV+ head and neck cancers with HPV believed to be the causative factor in approximately 75% of such cancer cases. HPV is also associated with cervical, anal, vulvar, penis and other cancers. Reflecting an increase in the importance of HPV+ cancers, they were the subject of this year’s Karnofsky Lecture at the American Society of Clinical Oncology (“ASCO”)
21
Table of Contents
meeting in June 2021. More broadly, many other cancers are believed to be associated with or caused by viruses including hepatoma, lymphomas, brain tumors, skin cancer and others. We believe that, if successfully developed and approved, mupadolimab’s mechanism and unique properties could position it as new treatment option for these viral associated cancers.
In our ongoing Phase 1/1b cancer clinical trial with mupadolimab, we have observed evidence of anti-tumor activity in oropharyngeal cancers associated with HPV infection. Based on these findings, during the second quarter, we began enrolling an expansion cohort of up to 15 patients with advanced, HPV+ head and neck cancer that have failed treatment with anti-PD-1 antibodies and chemotherapy. In this cohort, mupadolimab will be given in combination with pembrolizumab. Our goal is to present data from this expansion cohort at a medical meeting later this year. Our objective in this study is to evaluate response rate.
Our next product candidate, CPI-818, is a selective, covalent inhibitor of ITK and is in a multi-center Phase 1/1b clinical trial in patients with various malignant T-cell lymphomas. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells, and we believe it also has the potential to regulate the growth of abnormal T cells involved in autoimmunity. CPI-818 is currently being studied in a Phase 1/1b clinical in patients with several types of advanced, refractory T cell lymphomas at sites in the United States, Australia, and South Korea. Interim data from the Phase 1/1b clinical trial of CPI-818 for T cell lymphoma demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies. As of March 4, 2021, and reported in December 2020 at the meeting of the American Society of Hematology, of seven patients with PTCL, there had been one complete response lasting over 15 months and one partial response lasting for over five months; both responses are ongoing. Based on interim data from our Phase 1/1b clinical trial, Angel Pharmaceuticals submitted an investigational new drug application (IND) for CPI-818 in July 2021 in China. If this IND is approved, Angel plans to initiate a Phase 1b/2 clinical trial of CPI-818 for the treatment of refractory T cell lymphomas in late 2021, with the potential to expand into autoimmune diseases over time.
Our third product candidate, ciforadenant (formerly CPI-444), is an oral, small molecule antagonist of the A2A receptor for adenosine with which we completed a Phase 2 expansion protocol in combination with Genentech, Inc.’s cancer immunotherapy, Tecentriq® (atezolizumab) for patients with either advanced or refractory renal cell cancer (“RCC”). Ciforadenant is designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of adenosine in the tumor microenvironment to the A2A receptor. We also discovered the Adenosine Gene Signature, which has demonstrated the potential to serve as a biomarker to identify patients most likely to respond to treatment with ciforadenant. We have refined our strategy with ciforadenant and plan to collaborate with the Kidney Cancer Consortium to evaluate ciforadenant in a Phase 2 clinical trial in first-line therapy for metastatic RCC in combination with pembrolizumab and a tyrosine kinase inhibitor. The trial is expected to enroll up to 60 patients and is intended to increase complete responses and deep responses in the front-line setting. Preclinical studies indicate adenosine may be a cause of resistance to current therapies with anti PD(L)-1 and tyrosine kinase inhibitors. Tumor biopsies will be evaluated for expression of the Adenosine Gene Signature.
To date, the majority of our efforts have been focused on the research, development and advancement of mupadolimab, CPI-818 and ciforadenant, and we have not generated any revenue from product sales and, as a result, we have incurred significant losses. We expect to continue to incur significant research and development and general and administrative expenses related to our operations. Our net loss for the three and six months ended June 30, 2021 was $11.8 million and $23.3 million, respectively. As of June 30, 2021, we had an accumulated deficit of $246.5 million. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase as we continue our development of, seek regulatory approval for and begin to commercialize mupadolimab, CPI-818 and ciforadenant, and as we develop other product candidates. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods.
Since our inception and through June 30, 2021, we have funded our operations primarily through the sale and issuance of stock. In March 2018, in a follow-on offering, we sold 8,117,647 shares of our common stock at a price of $8.50 per share, which included 1,058,823 shares issued pursuant to the underwriters’ exercise of their option to purchase additional shares of common stock. We received aggregate net proceeds of approximately $64.9 million, after underwriting discounts, commissions and offering expenses. In February 2021, we completed a follow-on public offering in which we sold 9,783,660 shares of common stock at a price of $3.50 per share, which included 1,212,231
22
Table of Contents
shares issued pursuant to the underwriters’ exercise of their option to purchase additional shares of common stock. We received aggregate net proceeds of approximately $32.0 million, net of underwriting discounts and commissions and offering expenses.
In March 2020, we entered into an open market sales agreement (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) to sell shares of the Company’s common stock, from time to time, with aggregate gross sales proceeds of up to $50,000,000, through an at-the-market equity offering program under which Jefferies acts as our sales agent. Jefferies is entitled to compensation for its services equal to 3.0% of the gross proceeds of any shares of common stock sold through Jefferies under the Sales Agreement. During the six months ended June 30, 2021, the Company sold 4,264,865 shares under its at-the-market offering program resulting in net proceeds of $11.8 million. As of June 30, 2021, $36.6 million remained for sale under the Sales Agreement.
In October 2020, we announced the formation and launch of Angel Pharmaceuticals Co., Ltd. (“Angel Pharmaceuticals”), a new China based biopharmaceutical company with a mission to bring innovative quality medicines to Chinese patients for treatment of serious diseases including cancer, autoimmune diseases and infectious diseases. We formed Angel Pharmaceuticals as a wholly owned subsidiary and it launched with a post-money valuation of approximately $106.0 million, based on an approximate $41.0 million cash investment from a Chinese investor group that includes funds associated with Tigermed and Betta Pharmaceuticals, Hisun Pharmaceuticals and Zhejiang Puissance Capital. Such cash is not available for our use. Contemporaneously with the financing, Angel Pharmaceuticals licensed the rights to develop and commercialize our three clinical-stage candidates – mupadolimab, CPI-818 and ciforadenant – in greater China and obtained global rights to our BTK inhibitor preclinical programs. Under the collaboration, we currently have a 49.7% equity interest in Angel Pharmaceuticals, excluding 7% of Angel’s equity reserved for issuance under the Angel ESOP, and are entitled to designate three individuals on Angel’s five-person Board of Directors.
As of June 30, 2021, we had capital resources consisting of cash, cash equivalents and marketable securities of approximately $66.5 million. We do not expect our existing capital resources to be sufficient to enable us to fund the completion of all of our ongoing or planned clinical trials and remaining development program of any of mupadolimab, CPI-818 or ciforadenant through commercialization. In addition, our operating plan may change as a result of many factors, including those described in the section of this report entitled “Risk Factors” and others currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity, debt financings or other sources, such as strategic collaborations. Such financing would result in dilution to stockholders, imposition of debt covenants and repayment obligations or other restrictions that may affect our business. If we raise additional capital through strategic collaboration agreements, we may have to relinquish valuable rights to our product candidates, including possible future revenue streams. In addition, additional funding may not be available to us on acceptable terms or at all and any additional fundraising efforts may divert our management from its day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Furthermore, even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital due to favorable market conditions or strategic considerations.
We currently have no manufacturing capabilities and do not intend to establish any such capabilities. We have no commercial manufacturing facilities for our product candidates. As such, we are dependent on third parties to supply our product candidates according to our specifications, in sufficient quantities, on time, in compliance with appropriate regulatory standards and at competitive prices.
Impact of COVID-19
COVID-19 has placed strains on the providers of healthcare services, including the healthcare institutions where we conduct our clinical trials. These strains have resulted in institutions prohibiting the initiation of new clinical trials, enrollment in existing clinical trials and restricting the on-site monitoring of clinical trials. We also follow FDA guidance on clinical trial conduct during the COVID-19 pandemic, including the remote monitoring of clinical data.
In alignment with public health guidance designed to slow the spread of COVID-19, as of mid-March 2020, we implemented a reduced onsite staffing model and transitioned to a remote work plan for all employees other than those providing essential services, such as our laboratory staff. In July 2021, we started transitioning back to office work for
23
Table of Contents
employees not providing essential services. For our onsite employees, we have implemented heightened health and safety measures designed to comply with applicable federal, state and local guidelines in response to the COVID-19 pandemic. We are further supporting all of our employees by leveraging virtual meeting technology and encouraging employees to follow local health authority guidance. We may need to undertake additional actions that could impact our operations if required by applicable laws or regulations or if we determine such actions to be in the best interests of our employees.
Significant Accounting Policies
Our significant accounting policies are described in Note 2 to our consolidated financial statements for the year ended December 31, 2020 included in our Annual Report on Form 10-K. There have been no material changes to our significant accounting policies during the six months ended June 30, 2021.
Components of Results of Operations
Revenue
To date, we have not generated any revenues. We do not expect to receive any revenues from any product candidates that we develop unless and until we obtain regulatory approval and commercialize our products or enter into revenue-generating collaboration agreements with third parties.
Research and Development Expense
Our research and development expenses consist primarily of costs incurred to conduct research and development of our product candidates. We record research and development expenses as incurred. Research and development expenses include:
● employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense;
● external research and development expenses incurred under arrangements with third parties, such as contract research organizations, preclinical testing organizations, contract manufacturing organizations, academic and non-profit institutions and consultants;
● costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use;
● license fees; and
● other expenses, which include direct and allocated expenses for laboratory, facilities and other costs.
We plan to increase our research and development expenses substantially as we continue the development and potential commercialization of our product candidates. Our current planned research and development activities include the following:
● enrollment and completion of our Phase 1/1b clinical trial of mupadolimab in patients with advanced, HPV+ head and neck cancer;
● enrollment and completion of our ongoing Phase 1/1b clinical trial of CPI-818;
● process development and manufacturing of drug supply of mupadolimab, CPI-818 and ciforadenant; and
● preclinical studies under our other programs in order to select development product candidates.
24
Table of Contents
In addition to our product candidates that are in clinical development, we believe it is important to continue substantial investment in potential new product candidates to build the value of our product candidate pipeline and our business.
Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties related to timing and cost to completion. The duration, costs and timing of clinical trials and development of product candidates will depend on a variety of factors, including many of which are beyond our control. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time consuming, and the successful development of our product candidates is uncertain. The risks and uncertainties associated with our research and development projects are discussed more fully in “Part II, Item 1A—Risk Factors.” As a result of these risks and uncertainties, we are unable to determine with any degree of certainty the duration and completion costs of our research and development projects or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates.
General and Administrative Expenses
General and administrative expenses include personnel costs, expenses for outside professional services and allocated expenses. Personnel costs consist of salaries, benefits and stock-based compensation. Outside professional services consist of legal, accounting and audit services and other consulting fees. Allocated expenses consist of rent expense related to our office and research and development facility.
We expect that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research and development and potential commercialization of one or more of our product candidates.
Results of Operations
Comparison of the periods below as indicated (in thousands) :
Three Months Ended
Six Months Ended
June 30,
June 30,
2021
2020
Change
2021
2020
Change
Operating expenses:
Research and development
$
9,106
$
7,857
$
1,249
$
17,336
$
18,020
$
(684)
General and administrative
2,184
2,910
(726)
5,437
6,016
(579)
Total operating expenses
11,290
10,767
523
22,773
24,036
(1,263)
Loss from operations
(11,290)
(10,767)
(523)
(22,773)
(24,036)
1,263
Interest income and other expense, net
1
156
(155)
4
490
(486)
Loss from equity method investment
(463)
—
(463)
(563)
—
(563)
Net loss
$
(11,752)
$
(10,611)
$
(1,141)
$
(23,332)
$
(23,546)
$
214
25
Table of Contents
Research and Development Expense
Research and development expenses for the three and six months ended June 30, 2021 and 2020 consisted of the following costs by program (specific program costs consist solely of external costs)(in thousands):
Three Months Ended
Six Months Ended
June 30,
June 30,
2021
2020
Change
2021
2020
Change
Ciforadenant (formerly CPI-444)
$
457
$
1,030
$
(573)
$
861
$
2,262
$
(1,401)
Mupadolimab (formerly CPI‑006)
4,970
1,969
3,001
8,967
4,633
4,334
CPI-818
296
607
(311)
590
1,739
(1,149)
Other programs
4
215
(211)
8
812
(804)
Unallocated employee and overhead costs
3,379
4,036
(657)
6,910
8,574
(1,664)
$
9,106
$
7,857
$
1,249
$
17,336
$
18,020
$
(684)
For the three months ended June 30, 2021, the decrease in ciforadenant costs of $0.6 million as compared to the three months ended June 30, 2020, primarily consisted of a decrease of $0.4 million in clinical trial expenses and a decrease of $0.2 million in other outside service costs.
For the six months ended June 30, 2021, the decrease in ciforadenant costs of $1.4 million as compared to the six months ended June 30, 2020, primarily consisted of a decrease of $1.1 million in clinical trial expenses and a decrease of $0.3 million in other outside service costs.
For the three months ended June 30, 2021, the increase in mupadolimab costs of $3.0 million as compared to the three months ended June 30, 2020, primarily consisted of an increase of $2.4 million in clinical trial expenses, an increase of $0.4 million in drug manufacturing costs and in increase of $0.2 million in other outside services associated with the initiation of the Company’s COVID-19 Phase 3 clinical trial.
For the six months ended June 30, 2021, the increase in mupadolimab costs of $4.3 million as compared to the six months ended June 30, 2020, primarily consisted of an increase of $3.3 million in clinical trial expenses, an increase of $0.4 million in licensing expense, an increase of $0.5 million in drug manufacturing costs and in increase of $0.1 million in other outside service costs associated with the initiation of the our COVID-19 Phase 3 clinical trial.
For the three months ended June 30, 2021, the decrease in CPI-818 costs of $0.3 million as compared to the three months ended June 30, 2020, primarily consisted of a decrease in clinical trial expenses.
For the six months ended June 30, 2021, the decrease in CPI-818 costs of $1.1 million as compared to the six months ended June 30, 2020, primarily consisted of a decrease of $0.7 million in clinical trial expenses and a decrease of $0.4 million in drug manufacturing costs.
For the three months ended June 30, 2021, the decrease in other program costs of $0.2 million as compared to the three months ended June 30, 2020, primarily consisted of a decrease in drug manufacturing costs.
For the six months ended June 30, 2021, the decrease in other program costs of $0.8 million as compared to the six months ended June 30, 2020, primarily consisted of a decrease of $0.7 million in drug manufacturing costs and a decrease of $0.1 million in other outside services costs .
For the three months ended June 30, 2021, the decrease in unallocated costs of $0.7 million as compared to the three months ended June 30, 2020, primarily consisted of a decrease of $0.6 million in personnel and related costs and a decrease of $0.1 million in other outside service costs.
For the six months ended June 30, 2021, the decrease in unallocated costs of $1.7 million as compared to the six months ended June 30, 2020, primarily consisted of a decrease of $1.3 million in personnel and related costs and a decrease of $0.4 million in other outside service costs.
26
Table of Contents
General and Administrative Expense
For the three months ended June 30, 2021, the decrease in general and administrative expenses of $0.7 million as compared to the three months ended June 30, 2020, primarily consisted of a decrease of $0.4 million in professional service costs and a decrease of $0.3 million in personnel and related costs.
For the six months ended June 30, 2021, the decrease in general and administrative expenses of $0.6 million as compared to the six months ended June 30, 2020, primarily consisted of a decrease of $0.5 million in personnel and related costs and a decrease of $0.1 million in professional service costs.
Interest Income and Other Expense, net
For the three months ended June 30, 2021, the decrease in interest income and other expense, net of $0.2 million as compared to the three months ended June 30, 2020, primarily consisted of a decrease in interest income earned due to a decrease in interest rates.
For the six months ended June 30, 2021, the decrease in interest income and other expense, net of $0.5 million as compared to the six months ended June 30, 2020, primarily consisted of a decrease in interest income earned due to a decrease in interest rates.
Loss from equity method investment
For the three months ended June 30, 2021, the loss from equity method investment of $0.5 million represents our share of Angel Pharmaceutical’s loss for the period.
For the six months ended June 30, 2021, the loss from equity method investment of $0.6 million represents our share of Angel Pharmaceutical’s loss for the period.
Liquidity and Capital Resources
As of June 30, 2021, we had cash, cash equivalents and marketable securities of $66.5 million, and an accumulated deficit of $246.5 million, compared to cash and cash equivalents and marketable securities of $44.3 million and an accumulated deficit of $223.1 million as of December 31, 2020. We have financed our operations primarily through private placements of convertible preferred stock and the sale of common stock.
In March 2016, we consummated our IPO and sold 4,700,000 shares of our common stock at a price of $15.00 per share, and in April 2016, sold 502,618 shares at a price of $15.00 per share pursuant to the partial exercise of the underwriters’ option to purchase additional shares of common stock. We received net proceeds of approximately $70.6 million, after deducting underwriting discounts, commissions and offering expenses. Immediately prior to the consummation of our IPO, all outstanding shares of the convertible preferred stock were converted into common stock on a one-for-one basis.
In March 2018, in a follow-on offering, we sold 8,117,647 shares of our common stock at a price of $8.50 per share, which included 1,058,823 shares issued pursuant to the underwriters’ exercise of their option to purchase additional shares of common stock. We received aggregate net proceeds of approximately $64.9 million, after underwriting discounts, commissions and offering expenses.
In February 2021, we completed a follow-on public offering in which we sold 9,783,660 shares of common stock at a price of $3.50 per share, which included 1,212,231 shares issued pursuant to the underwriters’ exercise of their option to purchase additional shares of common stock. We received aggregate net proceeds of approximately $32.0 million, net of underwriting discounts and commissions and offering expenses.
27
Table of Contents
In March 2020, we entered into a Sales Agreement (“the “Sales Agreement”) with Jefferies LLC (“Jefferies”) to sell shares of the Company’s common stock, from time to time, with aggregate gross sales proceeds of up to $50.0 million, through an at the market equity offering program under which Jefferies acts as our sales agent. Jefferies is entitled to compensation for its services equal to up to 3.0% of the gross proceeds of any shares of common stock sold through Jefferies under the Sales Agreement. During the six months ended June 30, 2021, the Company sold 4,264,865 shares under its at-the-market offering program resulting in net proceeds of $11.8 million. As of June 30, 2021, $36.6 million remained for sale under the Sales Agreement.
We believe our current cash, cash equivalents and marketable securities will be sufficient to fund our planned expenditures and meet our obligations through at least the next twelve months from the issuance of our financial statements as of and for the three and six months ended June 30, 2021. The amounts and timing of our actual expenditures depend on numerous factors, including:
● the progress, timing, costs and results of clinical trials for mupadolimab, CPI-818 and ciforadenant;
● the extent to which the COVID-19 coronavirus may impact our business, including our clinical trials and financial condition;
● the timing, progress, costs and results of preclinical and clinical development activities for our other product candidates;
● the number and scope of preclinical and clinical programs we decide to pursue;
● the costs involved in prosecuting, maintaining and enforcing patent and other intellectual property rights;
● the cost and timing of regulatory approvals;
● our efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates and satisfy our obligations as a public company; and
● other factors described in the section of this report entitled “Risk Factors.”
We expect to increase our spending in connection with the development and commercialization of our product candidates. Until such time, if ever, as we can generate substantial revenue from product sales, we expect to fund our operations and capital funding needs through equity and/or debt financings. We may also enter into additional collaboration arrangements or selectively partner for clinical development and commercialization. The sale of additional equity would result in dilution to our stockholders. The incurrence of debt financing would result in debt service obligations and the governing documents would likely include operating and financing covenants that would restrict our operations. In addition, sufficient additional funding may not be available on acceptable terms, or at all. If we are not able to secure adequate additional funding, we may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible and/or suspend or curtail planned programs. Any of these actions could have a material effect on our business, financial condition and results of operations.
28
Table of Contents
Summary of Statement of Cash Flows
The following table summarizes our cash flows for the periods indicated (in thousands):
Six Months Ended
June 30,
2021
2020
Net cash provided by (used in):
Operating activities
$
(21,434)
$
(18,839)
Investing activities
20,088
34,367
Financing activities
43,806
23
Net increase in cash and cash equivalents
$
42,460
$
15,551
Cash Flows from Operating Activities
Cash used in operating activities during the six months ended June 30, 2021 was $21.4 million, which primarily consisted of a net loss of $23.3 million, adjusted by non-cash charges of $3.4 million, primarily consisting of $2.4 million of stock compensation expense, an increase of $1.6 million in prepaid and other current assets and an increase of $0.1 million in accounts payable and accrued and other current liabilities.
Cash used in operating activities during the six months ended June 30, 2020 was $18.8 million, which primarily consisted of a net loss of $23.5 million, adjusted by non-cash charges of $3.5 million, primarily consisting of $3.2 million of stock compensation expense, and an increase of $1.2 million in accounts payable and accrued and other current liabilities.
Cash Flows from Investing Activities
During the six months ended June 30, 2021, cash provided in investing activities was $20.1 million, which consisted of proceeds from maturities of marketable securities of $24.8 million, partially offset by purchases of marketable securities of $4.7 million.
During the six months ended June 30, 2020, cash provided in investing activities was $34.4 million, which consisted of proceeds from maturities of marketable securities of $63.1 million and proceeds from sales of marketable securities of $1.0 million, partially offset by purchases of marketable securities of $29.7 million.
Cash Flows from Financing Activities
During the six months ended June 30, 2021, cash provided by financing activities was $43.8 million, which consisted of $32.0 million in net proceeds from our February 2021 follow-on public offering and $11.8 million in net proceeds from the issuance of common stock through our at-the-market offering program.
During the six months ended June 30, 2020, cash provided by financing activities was negligible.
Contractual Obligations
There have been no material changes outside the ordinary course of our business to our contractual obligations during the six months ended June 30, 2021, as compared to those disclosed in our Annual Report on Form 10-K.
JOBS Act Accounting Election
We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this
29
Table of Contents
exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. We also rely on other exemptions provided by the JOBS Act, including, without limitation, providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act. We will remain an emerging growth company until the earlier of (1) December 31, 2021, (2) the last day of the fiscal year in which we have total annual gross revenue of at least $1.07 billion, (3) the last day of the fiscal year in which we are deemed to be a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock that is held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such fiscal year, or (4) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period. Even after we no longer qualify as an emerging growth company, we may still qualify as a “smaller reporting company” which may allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.